Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
5.98 ^DKK	+2.05%		-.--%	-17.63%

05-27	Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001	CI
05-15	Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024

May 15, 2024 at 10:26 am

Cessatech A/S reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was DKK 2.71 million compared to DKK 4.37 million a year ago. Basic loss per share from continuing operations was DKK 0.16 compared to DKK 0.32 a year ago.

Diluted loss per share from continuing operations was DKK 0.16 compared to DKK 0.32 a year ago.

Latest news about Cessatech A/S

Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001	05-27	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	25/10/23	CI
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	21/09/23	CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	12/09/23	MT
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation	12/09/23	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Cessatech A/S Secures DKK 5 Million Loan Facility Agreement to Support the US Launch of its Lead Program CT001	17/08/23	CI
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001	27/06/23	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	29/04/23	CI
Cessatech A/S Appoints Martin Olin as the Chairman of the Board	23/03/23	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	01/03/23	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
Cessatech A/S Auditor Raises 'Going Concern' Doubt	27/02/23	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	18/11/22	CI
Cessatech to Raise $2 Million in Rights Offer	14/11/22	MT
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate	23/09/22	CI
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate	05/09/22	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	19/08/22	CI
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval	30/06/22	CI
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate	16/05/22	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	19/04/22	CI
Cessatech A/S Announces Board Changes	17/03/22	CI

Chart Cessatech A/S

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data